ArticleBlood vessels, thrombosis & hemostasis2026
Molecular control of platelet extravasation into tumors and its impact on tumor growth.
Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets are considered intravascular effectors of hemostasis, yet growing evidence indicates that they can migrate across the endothelium. Whether platelet exit from the vasculature is a regulated process analogous to leukocyte trafficking and how migration is coordinated with effector functions has remained unclear. Using genetic, pharmacologic, and imaging approaches, we define the molecular program governing platelet transendothelial migration into tumors in vivo. CXCL12-CXCR4 signaling contributed to platelet extravasation in vivo, with stromal rather than tumor-derived CXCL12 acting as the dominant cue; CXCR4 disruption reduced platelet infiltration and tumor growth. Efficient vascular exit required platelet focal adhesion kinase and platelet endothelial cell adhesion molecule 1, implicating cytoskeletal remodeling and junctional adhesion. Platelet trafficking was uncoupled from effector activity: Munc13-4-dependent dense granule secretion was dispensable for extravasation but required for growth promotion, whereas Munc18-2-regulated α-granule release preserved vascular integrity and restricted passage. Disruption of the CLEC-2/podoplanin axis destabilized vessels and increased leakage. Together, these findings establish regulated platelet extravasation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.